1. Home
  2. UCAR vs GRDX Comparison

UCAR vs GRDX Comparison

Compare UCAR & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U Power Limited

UCAR

U Power Limited

HOLD

Current Price

$3.00

Market Cap

6.9M

ML Signal

HOLD

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

N/A

Current Price

$5.80

Market Cap

28.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UCAR
GRDX
Founded
2013
N/A
Country
China
United Kingdom
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9M
28.6M
IPO Year
2022
2016

Fundamental Metrics

Financial Performance
Metric
UCAR
GRDX
Price
$3.00
$5.80
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.5K
★ 102.3K
Earning Date
11-06-2026
11-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 21.95
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$13.33
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.04
$1.87
52 Week High
$8.99
$6.93

Technical Indicators

Market Signals
Indicator
UCAR
GRDX
Relative Strength Index (RSI) 44.70 61.41
Support Level $1.05 $2.35
Resistance Level $4.87 $6.00
Average True Range (ATR) 0.31 0.60
MACD -0.02 -0.01
Stochastic Oscillator 51.96 82.67

Price Performance

Historical Comparison
UCAR
GRDX

About UCAR U Power Limited

U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: